Key Developments: Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

25 Jul 2014
Price Change (% chg)

¥19 (+1.01%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Arqule Inc And Daiichi Sankyo Co Ltd Announces Discontinuation Of Phase 3 MARQUEE Clinical Trial In Non-Small Cell Lung Cancer
Tuesday, 2 Oct 2012 07:30am EDT 

Arqule Inc and Daiichi Sankyo Co Ltd announced that the independent Data Monitoring Committee (DMC) of the Phase 3 MARQUEE (Met inhibitor ARQ 197 plus Erlotinib vs Erlotinib plus placebo in NSCLC) trial recommended the study be stopped early following a planned interim analysis, when they concluded that the study would not meet primary endpoint of improved overall survival. Although the interim analysis showed a statistically significant improvement in progression-free survival (PFS) in the intent-to-treat (ITT) population, this benefit did not carry over to overall survival. There were no safety concerns identified by the DMC to Daiichi Sankyo or ArQule during this interim analysis. ArQule and Daiichi Sankyo are providing information regarding the study discontinuation to health authorities and those clinical investigators participating in studies of tivantinib.  Full Article

Daiichi Sankyo Co Ltd Result of Phase III Clinical Trial for Antiplatelet Drug
Friday, 21 Sep 2012 03:00am EDT 

Daiichi Sankyo Co Ltd announced the result of the domestic phase III clinical trial for its antiplatelet Drug. The phase III clinical trial confirmed the dose-response and the safety of the drug.  Full Article

Daiichi Sankyo Co Ltd and Eli Lilly And Co Announce TRILOGY ACS Results
Sunday, 26 Aug 2012 02:00am EDT 

Daiichi Sankyo Co Ltd and Eli Lilly And Co announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an artery-opening procedure. At 30 months, 13.9 percent of prasugrel patients versus 16.0 percent of clopidogrel patients experienced the combined primary endpoint of heart attack, stroke or cardiovascular (CV) death in patients under 75 years of age, the primary analysis population (HR=0.91; 95% CI: 0.79-1.05).1 This outcome was not statistically significant (P=0.21). Different from other trials, TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes) prospectively studied only the UA/NSTEMI population medically managed without revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery).  Full Article

Search Stocks